271 related articles for article (PubMed ID: 27240275)
1. Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.
Jia L; Ma S
Eur J Med Chem; 2016 Oct; 121():209-220. PubMed ID: 27240275
[TBL] [Abstract][Full Text] [Related]
2. Development of heparanase inhibitors for anti-cancer therapy.
Miao HQ; Liu H; Navarro E; Kussie P; Zhu Z
Curr Med Chem; 2006; 13(18):2101-11. PubMed ID: 16918340
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.
Baburajeev CP; Mohan CD; Rangappa S; Mason DJ; Fuchs JE; Bender A; Barash U; Vlodavsky I; Basappa ; Rangappa KS
BMC Cancer; 2017 Mar; 17(1):235. PubMed ID: 28359266
[TBL] [Abstract][Full Text] [Related]
5. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase.
Wilson JC; Laloo AE; Singh S; Ferro V
Biochem Biophys Res Commun; 2014 Jan; 443(1):185-8. PubMed ID: 24291708
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances.
Fu K; Bai Z; Chen L; Ye W; Wang M; Hu J; Liu C; Zhou W
Eur J Med Chem; 2020 May; 193():112221. PubMed ID: 32222663
[TBL] [Abstract][Full Text] [Related]
7. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
8. Heparanase: Historical Aspects and Future Perspectives.
Khanna M; Parish CR
Adv Exp Med Biol; 2020; 1221():71-96. PubMed ID: 32274707
[TBL] [Abstract][Full Text] [Related]
9. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Vlodavsky I; Ilan N; Naggi A; Casu B
Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
[TBL] [Abstract][Full Text] [Related]
10. Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors.
Rondanin R; Fochi S; Baruchello R; Bernardi T; Oliva P; Semeraro F; Simoni D; Giannini G
Bioorg Med Chem Lett; 2017 Sep; 27(18):4421-4425. PubMed ID: 28811133
[TBL] [Abstract][Full Text] [Related]
11. The Heparanase Regulatory Network in Health and Disease.
Mayfosh AJ; Nguyen TK; Hulett MD
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681753
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.
Ishida K; Hirai G; Murakami K; Teruya T; Simizu S; Sodeoka M; Osada H
Mol Cancer Ther; 2004 Sep; 3(9):1069-77. PubMed ID: 15367701
[TBL] [Abstract][Full Text] [Related]
13. Chemical toolbox to interrogate Heparanase-1 activity.
Rabinowitz ZM; Somers J; Wang Z; Cui L
Curr Opin Chem Biol; 2024 Jun; 80():102452. PubMed ID: 38555836
[TBL] [Abstract][Full Text] [Related]
14. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
Lanzi C; Zaffaroni N; Cassinelli G
Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
[TBL] [Abstract][Full Text] [Related]
15. Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.
Zubkova OV; Ahmed YA; Guimond SE; Noble SL; Miller JH; Alfred Smith RA; Nurcombe V; Tyler PC; Weissmann M; Vlodavsky I; Turnbull JE
ACS Chem Biol; 2018 Dec; 13(12):3236-3242. PubMed ID: 30480427
[TBL] [Abstract][Full Text] [Related]
16. Heparanase: a target for drug discovery in cancer and inflammation.
McKenzie EA
Br J Pharmacol; 2007 May; 151(1):1-14. PubMed ID: 17339837
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
18. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
Schoenfeld AK; Vierfuß S; Lühn S; Alban S
J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
[TBL] [Abstract][Full Text] [Related]
19. Heparanase as a molecular target of cancer chemotherapy.
Simizu S; Ishida K; Osada H
Cancer Sci; 2004 Jul; 95(7):553-8. PubMed ID: 15245589
[TBL] [Abstract][Full Text] [Related]
20. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
Cassinelli G; Zaffaroni N; Lanzi C
Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
